当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.

Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population.

Abstract：

:As a recently launched novel vaccine used as one of the vaccines for the final eradication of polios worldwide, complete data on the consistency and immunogenicity characteristics of the inactivated poliomyelitis vaccine made from the Sabin strain (sIPV) and its safety in large-scale populations are required to support the future use of this vaccine worldwide. A phase IV clinical trial was conducted to perform an immunogenicity evaluation of lot-to-lot consistency of three commercial batches of sIPV in 1200 infants and to investigate the vaccine's safety on a large-scale in 20,019 infants for active monitoring and 29,683 infants for passive monitoring through the Adverse Event Following Immunization (AEFI) reporting system in China. In the immunogenicity evaluation, the average seroconversion rates for type I, type II and type III of the three groups were 99.83%, 98.93% and 99.44%, respectively. No differences in the seroconversion rate and the GMT ratios were noted in the pair-to-pair comparisons. In the large-scale safety evaluation, most adverse reactions occurred 0-30 days after the first doses, and the common local and systemic reactions were similar to those in the phase III clinical trial, with low incidence in both activated and passive monitoring. In conclusion, sIPV exhibits good lot-to-lot consistency and safety in large-scale populations; thus, it is qualified to serve as one of the vaccines for use in eradicating all wild and vaccine-derived polioviruses worldwide in the near future. Clinic Trial Registration. NCT04224519 and NCT04220515.

journal_name

Vaccine

journal_title

Vaccine

authors

Jiang R,Liu X,Sun X,Wang J,Huang Z,Li C,Li Z,Zhou J,Pu Y,Ying Z,Yin Q,Zhao Z,Zhang L,Lei J,Bao W,Jiang Y,Dou Y,Li J,Yang H,Cai W,Deng Y,Che Y,Shi L,Sun M

doi

10.1016/j.vaccine.2021.01.027

subject

Has Abstract

pub_date

2021-01-21 00:00:00

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(21)00043-8

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women.

    abstract：:Vaccination during pregnancy is increasingly being used as an effective approach for protecting both young infants and their mothers from serious infections. Drawing conclusions from published studies in this area can be difficult because of the inability to compare vaccine trial results across different studies and s...

    journal_title：Vaccine

    pub_type： 指南,杂志文章

    doi：10.1016/j.vaccine.2016.07.032

    authors： Jones CE,Munoz FM,Spiegel HM,Heininger U,Zuber PL,Edwards KM,Lambach P,Neels P,Kohl KS,Gidudu J,Hirschfeld S,Oleske JM,Khuri-Bulos N,Bauwens J,Eckert LO,Kochhar S,Bonhoeffer J,Heath PT,Brighton Collaboration Immunizat

    更新日期：2016-12-01 00:00:00

  • The potential economic value of a hookworm vaccine.

    abstract：:Hookworm infection is a significant problem worldwide. As development of hookworm vaccine proceeds, it is essential for vaccine developers and manufacturers, policy makers, and other public health officials to understand the potential costs and benefits of such a vaccine. We developed a decision analytic model to eval...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2010.12.004

    authors： Lee BY,Bacon KM,Bailey R,Wiringa AE,Smith KJ

    更新日期：2011-02-01 00:00:00

  • A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge.

    abstract：:Here we confirm that intranasal (IN) dry powder anthrax vaccine formulations are able to protect rabbits against aerosol challenge 9 weeks after a single immunization. The optimum dose of rPA in our dry powder anthrax vaccine formulation in rabbits was experimentally determined to be 150microg and therefore was chosen...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.07.062

    authors： Klas SD,Petrie CR,Warwood SJ,Williams MS,Olds CL,Stenz JP,Cheff AM,Hinchcliffe M,Richardson C,Wimer S

    更新日期：2008-10-09 00:00:00

  • No major outbreaks of pseudorabies virus in well-immunized sow herds.

    abstract：:In this study we quantified the transmission of pseudorabies virus (PRV) in well-immunized sow herds in The Netherlands. In three herds, sows were tested for antibodies to gE of PRV every time after they had been transported to another barn (survey A). In 99 other herds, sows were tested simultaneously once or twice y...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(96)00022-9

    authors： Van Nes A,Stegeman JA,De Jong MC,Loeffen WL,Kimman TG,Verheijden JH

    更新日期：1996-08-01 00:00:00

  • Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study.

    abstract：:The bioavailability of oseltamivir phosphate and oseltamivir carboxylate were assessed in healthy volunteers when delivered as a solution of the active pharmaceutical ingredient (API) compared with the commercial capsule formulation. The 90% confidence intervals (CIs) for the ratios of the two treatments (capsule vers...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2006.05.080

    authors： Brewster M,Smith JR,Dutkowski R,Robson R

    更新日期：2006-11-10 00:00:00

  • Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium.

    abstract：:For the production of a chemically inactivated Parapoxvirus ovis (PPVO), an adherent bovine kidney cell line was cultivated on Cytodex-3 microcarriers in suspension culture. The inactivated and purified virus particles have shown immune modulatory activity in several animal models. PPVO was produced by a biphasic batc...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.01.032

    authors： Pohlscheidt M,Langer U,Minuth T,Bödeker B,Apeler H,Hörlein HD,Paulsen D,Rübsamen-Waigmann H,Henzler HJ,Reichl U

    更新日期：2008-03-17 00:00:00

  • Evidence supporting the hypothesis that specifically modifying a malaria peptide to fit into HLA-DRbeta1*03 molecules induces antibody production and protection.

    abstract：:EBA-175 protein is used as ligand in Plasmodium falciparum binding to erythrocytes. Evidence shows that conserved peptide 1815 from this protein having high red blood cell binding ability plays an important role in the invasion process. This peptide is neither immunogenic nor protective. Residues were substituted by a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.08.052

    authors： Cifuentes G,Salazar LM,Vargas LE,Parra CA,Vanegas M,Cortes J,Patarroyo ME

    更新日期：2005-02-18 00:00:00

  • Synthetic gonadotrophin-releasing hormone (GnRH) vaccines incorporating GnRH and synthetic T-helper epitopes.

    abstract：:A vaccine against the gonadotrophin-releasing hormone (GnRH) is being developed as an immunological method for treatment of prostatic hypertrophy, based on the observation that active immunization against GnRH leads to the production of anti-GnRH antibodies which results in the shrinkage of the prostate gland. We have...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(93)90077-b

    authors： Sad S,Chauhan VS,Arunan K,Raghupathy R

    更新日期：1993-01-01 00:00:00

  • Serological evaluation of poliomyelitis oral and inactivated vaccines in an urban low-income population at Rio de Janeiro, Brazil.

    abstract：:Oral and inactivated poliomyelitis vaccines (OPV and IPV), were given to 160 children two months old, in a low income population at Rio de Janeiro. The vaccination was repeated 2 and 4 months later, always in association with diphtheria, tetanus and pertussis (DPT) vaccine. Blood specimens were collected before vaccin...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/0264-410x(86)90048-4

    authors： Schatzmayr HG,Maurice Y,Fujita M,de Fillipis AM

    更新日期：1986-06-01 00:00:00

  • Immunogenicity and protective efficacy of an inactivated cell culture-derived Seneca Valley virus vaccine in pigs.

    abstract：:Seneca Valley virus (SVV) infection in pigs is associated with porcine idiopathic vesicular disease (PIVD). Outbreaks of SVV infection in pig herds have been reported in several Asia and Americas countries. Recently, a series of outbreaks of SVV infection occurred in China, Canada, Thailand and the United States. Howe...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.12.055

    authors： Yang F,Zhu Z,Cao W,Liu H,Zhang K,Tian H,Liu X,Zheng H

    更新日期：2018-02-01 00:00:00

  • Autovaccination of dairy cows to treat post partum metritis caused by Actinomyces pyogenes.

    abstract：:Autovaccines are therapeutic vaccines manufactured from a disease causing micro-organism for individual treatment of patients, animals, or sometimes herds to treat chronic or recurrent infections. Despite the common use of autovaccines in veterinary medicine, their mechanism of action, i.e. the immunologic effector me...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00025-1

    authors： Nolte O,Morscher J,Weiss HE,Sonntag H

    更新日期：2001-04-30 00:00:00

  • Multi-epitope DnaK peptide vaccine against S.Typhi: An in silico approach.

    abstract：:Salmonella is one of the key global causes of food and water borne enteric infections, responsible for significant morbidity and mortality worldwide especially in developing countries. Currently available vaccines against typhoid are moderately effective with several side effects and not efficacious against all Salmon...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.05.106

    authors： Verma S,Sugadev R,Kumar A,Chandna S,Ganju L,Bansal A

    更新日期：2018-06-27 00:00:00

  • Meningococcal-group B (MenB) vaccine series completion and adherence to dosing schedule in the United States: A retrospective analysis by vaccine and payer type.

    abstract：BACKGROUND:Two MenB vaccines with different dosing schedules are approved in the US: MenB-4C (2 doses) and MenB-FHbp (2-3 doses). Both vaccines were licensed on the basis of immunogenicity demonstrated after vaccine series completion. We evaluated vaccination completion and adherence to dosing schedules. METHODS:This ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.06.065

    authors： Packnett E,Irwin DE,Novy P,Watson PS,Whelan J,Moore-Schiltz L,Lucci M,Hogea C

    更新日期：2019-09-16 00:00:00

  • Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals.

    abstract：:The aims of this study were to evaluate the impact of hepatitis B vaccination on the changing pattern of HBV infection in a former hyperendemic area (Afragola, South Italy), and to assess the long-term persistence of anti-HBs in two cohorts of individuals vaccinated as infants 18 and 23 years ago. Our data shows a sig...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.01.044

    authors： Da Villa G,Romanò L,Sepe A,Iorio R,Paribello N,Zappa A,Zanetti AR

    更新日期：2007-04-20 00:00:00

  • A pcDNA-Ehcpadh vaccine against Entamoeba histolytica elicits a protective Th1-like response in hamster liver.

    abstract：:DNA vaccines are promising tools to fight parasitic diseases, including amoebiasis caused by the protozoan Entamoeba histolytica. Here we studied the immunogenicity and protective efficacy of a DNA vaccine against this parasite composed by the EhCPADH surface complex encoding genes (Ehcp112 and Ehadh112). EhCPADH is f...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2009.04.051

    authors： Martínez MB,Rodríguez MA,García-Rivera G,Sánchez T,Hernández-Pando R,Aguilar D,Orozco E

    更新日期：2009-06-24 00:00:00

  • Assessment of indirect protection from maternal influenza immunization among non-vaccinated household family members in a randomized controlled trial in Sarlahi, Nepal.

    abstract：:Influenza is a significant cause of morbidity and mortality worldwide, and the World Health Organization highly recommends maternal vaccination during pregnancy. The indirect effect of maternal vaccination on other close contacts other than newborns is unknown. To evaluate this, we conducted a nested substudy between ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.08.014

    authors： Newman KL,Stewart LM,Scott EM,Tielsch JM,Englund JA,Khatry SK,Mullany LC,LeClerq SC,Shrestha L,Kuypers JM,Chu HY,Katz J

    更新日期：2020-10-07 00:00:00

  • A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae.

    abstract：:The aim of this work was to evaluate the microencapsulation by spray-drying of inactivated Vibrio cholerae, using methacrylic copolymers Eudragit® L30D-55 and FS30D. The microparticles obtained presented a particle size around 3.0 μm. The preparation temperature affected the morphology and the antigenicity of micropar...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.05.098

    authors： Año G,Esquisabel A,Pastor M,Talavera A,Cedré B,Fernández S,Sifontes S,Aranguren Y,Falero G,García L,Solís RL,Pedraz JL

    更新日期：2011-08-05 00:00:00

  • Global Vaccine Action Plan Lessons Learned II: Stakeholder Perspectives.

    abstract：INTRODUCTION:The Global Vaccine Action Plan (GVAP), unanimously endorsed by the World Health Assembly in 2012, defined an ambitious strategy to improve immunization. At the end of the decade, significant progress has been made but four of the five GVAP goals are likely to be missed. This report describes a set of surve...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.05.048

    authors： Hwang A,Veira C,Malvolti S,Cherian T,MacDonald N,Steffen C,Jones I,Hinman A,Mantel C

    更新日期：2020-07-14 00:00:00

  • The Health Belief Model in predicting healthcare workers' intention for influenza vaccine uptake in Jordan.

    abstract：BACKGROUND:Theories of health behavior change are being inadequately adopted to understand the reasons behind low influenza vaccination rates among healthcare workers (HCWs). The Theory of Planned Behavior (TPB) is being used to predict intention-behavior relationship while the Health Belief Model (HBM) is being employ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.09.002

    authors： Alhalaseh L,Fayoumi H,Khalil B

    更新日期：2020-10-27 00:00:00

  • Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP.

    abstract：:Immunization with a combination of several virulence-associated proteins is one of the strategies of developing effective protein-based vaccines to enhance the protection against Streptococcus pneumoniae. In this study, we evaluated the protection effects against pneumococcal infection caused by S. pneumoniae TIGR4 in...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.04.069

    authors： Cao J,Chen D,Xu W,Chen T,Xu S,Luo J,Zhao Q,Liu B,Wang D,Zhang X,Shan Y,Yin Y

    更新日期：2007-06-28 00:00:00

  • Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection.

    abstract：BACKGROUND:This randomised, open label, phase I, immunotherapeutic study investigated the effects of interleukin (IL)-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human growth hormone (rhGH), and therapeutic immunisation (a Clade B DNA vaccine) on combination antiretroviral therapy (cART)-t...

    journal_title：Vaccine

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.vaccine.2014.09.072

    authors： Herasimtschuk A,Downey J,Nelson M,Moyle G,Mandalia S,Sikut R,Adojaan M,Stanescu I,Gotch F,Imami N

    更新日期：2014-12-05 00:00:00

  • Hepatitis A and B in children and adolescents--what can we learn from Puglia (Italy) and Catalonia (Spain)?

    abstract：:Viral hepatitis remains a major contributor to the global disease burden. Mass immunisation strategies against hepatitis B have been adopted by more than 90 developing and industrialised countries. Countries with low hepatitis A endemicity are experiencing cyclical outbreaks and an epidemiological shift, with larger n...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00193-6

    authors： Lopalco PL,Salleras L,Barbuti S,Germinario C,Bruguera M,Buti M,Domínguez A

    更新日期：2000-10-15 00:00:00

  • Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates.

    abstract：:We describe here the preclinical development of a dengue vaccine composed of recombinant subunit carboxy-truncated envelope (E) proteins (DEN-80E) for each of the four dengue serotypes. Immunogenicity and protective efficacy studies in Rhesus monkeys were conducted to evaluate monovalent and tetravalent DEN-80E vaccin...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.06.067

    authors： Govindarajan D,Meschino S,Guan L,Clements DE,ter Meulen JH,Casimiro DR,Coller BA,Bett AJ

    更新日期：2015-08-07 00:00:00

  • Influenza vaccine effectiveness against influenza-associated hospitalization in 2015/16 season, Beijing, China.

    abstract：BACKGROUND:Vaccination is recommended to prevent influenza virus infection and associated complications. This study aimed to estimate the influenza vaccine effectiveness (VE) against hospitalization in the 2015/16 season in Beijing. METHODS:Patients who were hospitalized in the 5 study hospitals between 1 Oct 2015 and...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.03.084

    authors： Zhang Y,Wu P,Feng L,Yang P,Pan Y,Feng S,Qin Y,Zheng J,Puig-Barberà J,Muscatello D,MacIntyre R,Cowling BJ,Yu H,Wang Q

    更新日期：2017-05-25 00:00:00

  • Seasonal influenza vaccine effectiveness against medically attended influenza illness among children aged 6-59 months, October 2011-September 2012: A matched test-negative case-control study in Suzhou, China.

    abstract：BACKGROUND:Seasonal influenza infections among young children in China lead to substantial numbers of hospitalizations and financial burden. This study assessed the seasonal influenza vaccine effectiveness (VE) against laboratory confirmed medically attended influenza illness among children in Suzhou, China, from Octob...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.03.056

    authors： Wang Y,Zhang T,Chen L,Greene C,Ding Y,Cheng Y,Yang C,Zeng S,Hua J,Zhou S,Song Y,Luan L,Zhang J,Zhao G

    更新日期：2016-05-05 00:00:00

  • Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes.

    abstract：:The divergence of regulatory requirements and processes in developing and emerging countries contributes to hamper vaccines' registration, and therefore delay access to high-quality, safe and efficacious vaccines for their respective populations. This report focuses on providing insights on the heterogeneity of regist...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2018.03.049

    authors： Dellepiane N,Pagliusi S,Registration Experts Working Group.

    更新日期：2018-06-07 00:00:00

  • Evaluation of adenovirus 19a as a novel vector for mucosal vaccination against influenza A viruses.

    abstract：:Since preexisting immunity and enhanced infection rates in a clinical trial of an HIV vaccine have raised some concerns on adenovirus (Ad) serotype 5-based vaccines, we evaluated the subgroup D adenovirus serotype Ad19a for its suitability as novel viral vector vaccine against mucosal infections. In BALB/c mice, we co...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.02.075

    authors： Lapuente D,Ruzsics Z,Thirion C,Tenbusch M

    更新日期：2018-05-03 00:00:00

  • Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis.

    abstract：:Visceral leishmaniasis, caused by the intracellular parasite Leishmania donovani is a significant public health problem in many regions of the world. Anti-leishmanial immune defences are primarily dependent on the ability of the host to mount an interleukin-12 (IL-12) driven Th1 type of responses. Thus, IL-12 plays a ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2005.11.058

    authors： Tewary P,Saxena S,Madhubala R

    更新日期：2006-03-20 00:00:00

  • The impact of parental postpartum pertussis vaccination on infection in infants: A population-based study of cocooning in Western Australia.

    abstract：:During a pertussis epidemic in 2011-2012 the Western Australian (WA) Department of Health implemented a 'cocooning' programme, offering free pertussis-containing vaccine (dTpa) to new parents. We assessed the impact of vaccinating parents with dTpa on the incidence of pertussis infection in newborns. Births in WA duri...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2015.08.066

    authors： Carcione D,Regan AK,Tracey L,Mak DB,Gibbs R,Dowse GK,Bulsara M,Effler PV

    更新日期：2015-10-13 00:00:00

  • Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series.

    abstract：BACKGROUND:Annual seasonal influenza vaccination is recommended for transplant recipients. No formal pharmacoepidemiology study has been published on the association between solid organ transplant (SOT) rejection and vaccination with seasonal trivalent inactivated influenza vaccines (TIIVs). METHODS:The risk of SOT (l...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.05.016

    authors： Dos Santos G,Haguinet F,Cohet C,Webb D,Logie J,Ferreira GL,Rosillon D,Shinde V

    更新日期：2016-06-30 00:00:00